false 0001783328 0001783328 2023-05-17 2023-05-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 17, 2023

 

 

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40603   82-5282075

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

830 Winter Street,

Waltham, Massachusetts

   02451
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (857) 399-9500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trade

Symbol(s)

  

Name of each exchange

on which registered

Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On May 17, 2023, TScan Therapeutics, Inc. issued a press release announcing a poster presentation highlighting preliminary data from its Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting 2023. The full text of the press release is filed as Exhibit 99.1 on this Current Report on Form 8-K and incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits.

(d)    Exhibits.

The following exhibits are filed as part of this report:

 

Exhibit
Number		    Description
99.1    TScan Therapeutics, Inc. Press Release dated May 17, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TScan Therapeutics, Inc.
Date: May 17, 2023     By:  

/s/ Brian Silver

      Brian Silver
      Chief Financial Officer
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more TScan Therapeutics Charts.
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more TScan Therapeutics Charts.